Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,742 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,104 of 1,171 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,884 total, page 27 of 38
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
NCT00705250
Upper Extremity Lymphatic Mapping for Breast Cancer Patients
NCT00717886
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
NCT00675597
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00667615
Development of a Clinical Trial Specific Question Prompt List
NCT00662324
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
NCT00658385
Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial
NCT00639106
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
NCT00648037
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
NCT00671411
Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk
NCT00735150
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
NCT00629798
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
NCT00620633
Sensory Morbidity Following Breast Surgery
NCT00625924
Expressive Writing and Adjustment to Metastatic Breast Cancer
NCT00624156
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
NCT00610129
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
NCT00615901
Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients
NCT00574353
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
NCT00597272
Reconstructive Surgery For Head And Neck Cancer Patients
NCT00578032
The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
NCT00588705
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
NCT00574496
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
NCT00577707
Internal Radiation Therapy in Treating Patients With Prostate Cancer
NCT00573833
Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)
NCT00581958
Volumetric Analysis in the Assessment of Therapy Response by CT
NCT00582751
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NCT00661427
Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma
NCT00539643
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
NCT00567229
Cognitive Changes Associated With Breast Cancer Treatment
NCT00550134
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
NCT00562640
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
NCT00536874
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT00521014
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
NCT00561756
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
NCT00589784
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
NCT00550628
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
NCT00528450
Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure
NCT00530049
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
NCT00526292
Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device
NCT00607529
Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants
NCT00674648
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
NCT00505063
Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles
NCT00582192
Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women
NCT00519974
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant
NCT00510315
Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation
NCT00579800
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
NCT00522301
Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients
NCT00494910
Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors
NCT00496613
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
NCT00498927
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
NCT00410956
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Memorial Sloan Kettering Cancer Center: open-pipeline peers nationwide
Peers matched on 1,884 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Memorial Sloan Kettering Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,884 trials (± recruiting share)
- Pfizer · 1,845 trials · 6% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- ImmunityBio · 17% recruiting · 46 trials
- Old Dominion University · 17% recruiting · 23 trials
- Texas Tech University · 17% recruiting · 69 trials
- TransMedics · 17% recruiting · 23 trials
Related
What to do with this Memorial Sloan Kettering Cancer Center page
1,884 registered trials is a research-attention snapshot, not an endorsement of Memorial Sloan Kettering Cancer Center or any single study.
- 327 of Memorial Sloan Kettering Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Memorial Sloan Kettering Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Memorial Sloan Kettering Cancer Center pipeline card: 1,884 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.